Ignatzschineria indica (formerly known as the genus name Schineria) are non-motile, non-spore forming, aerobic gram-negative rods which are both catalase and oxidase positive. It is the second known genus of the class Gammaproteobacteria. Isolated from parasitic fly larvae, with optimal growth characteristics of pH 7.5 and temperature 37°C. While rarely causing disease in humans, I. indica has been emerging as a potential pathogen. Risk factors for infection include open wounds, poor hygiene, peripheral vascular disease, proximity to livestock, alcohol use disorder, older age, and lower socioeconomic status. General treatment of I. indica infection includes complete removal of larvae, sequential debridement, and antimicrobials. [1], [2]
A 2011 investigation evaluated two bacterial strains isolated from the gastrointestinal tract of adult flesh flies (Diptera: Sarcophagidae). The study used genetic sequencing, DNA-DNA hybridization, biochemical tests, and microscopic analysis to characterize the strains and determine their relationship to known bacteria. The results identified these strains as two novel species within the genus Ignatzschineria, named Ignatzschineria indica and Ignatzschineria ureiclastica. Both species were Gram-negative, aerobic, non-motile rods that grew well across temperatures of 4 to 45 °C, tolerated 0-6% salt concentrations, and grew in pH ranges of 6 to 9, with optimal growth at 37 °C, 2% NaCl, and pH 7.5. Additionally, both strains tested positive for catalase and oxidase enzyme activity. Ignatzschineria indica was negative for urease and hydrogen sulfide production, while Ignatzschineria ureiclastica tested positive for both. [1]
Antibiotic susceptibility testing showed that Ignatzschineria indica was sensitive to amikacin, azithromycin, cefaclor, ceftriaxone, cefotaxime, chloramphenicol, ciprofloxacin, clindamycin, erythromycin, gentamicin, kanamycin, nalidixic acid, netilmicin, nitrofurantoin, norfloxacin, ofloxacin, piperacillin/tazobactam, sparfloxacin, streptomycin, tetracycline, and tobramycin. Testing also revealed that Ignatzschineria indica was resistant to ampicillin, amoxicillin/clavulanate, aztreonam, cephalothin, colistin, mecillinam, metronidazole, penicillin, teicoplanin, ticarcillin, and vancomycin, with intermediate resistance to carbenicillin, ceftazidime, cephalexin, cephoxitin, co-trimoxazole, doxycycline, gatifloxacin, sulphamethoxazole, sulphatriad, and trimethoprim. Both strains shared major fatty acids, including C16:0, C18:1 isomers (v7c and/or v6c), CyC19:0 v8c, and C14:0, and contained the respiratory quinone Q-8. Together, the genetic, biochemical, and microscopic evidence supported defining these strains as two new species within the genus Ignatzschineria. [1]